Log in

NYSE:KOD - Kodiak Sciences Stock Price, Forecast & News

-0.91 (-1.87 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
Now: $47.84
50-Day Range
MA: $58.13
52-Week Range
Now: $47.84
Volume320,749 shs
Average Volume419,028 shs
Market Capitalization$2.13 billion
P/E RatioN/A
Dividend YieldN/A
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Read More

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$2.13 billion
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive KOD News and Ratings via Email

Sign-up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

Kodiak Sciences (NYSE:KOD) Frequently Asked Questions

How has Kodiak Sciences' stock been impacted by COVID-19 (Coronavirus)?

Kodiak Sciences' stock was trading at $53.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KOD stock has decreased by 11.2% and is now trading at $47.84. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kodiak Sciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kodiak Sciences.

When is Kodiak Sciences' next earnings date?

Kodiak Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Kodiak Sciences.

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NYSE:KOD) posted its quarterly earnings data on Monday, March, 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.05. View Kodiak Sciences' earnings history.

What price target have analysts set for KOD?

9 Wall Street analysts have issued twelve-month target prices for Kodiak Sciences' shares. Their forecasts range from $40.00 to $115.00. On average, they anticipate Kodiak Sciences' stock price to reach $85.44 in the next year. This suggests a possible upside of 78.6% from the stock's current price. View analysts' price targets for Kodiak Sciences.

What are Wall Street analysts saying about Kodiak Sciences stock?

Here are some recent quotes from research analysts about Kodiak Sciences stock:
  • 1. According to Zacks Investment Research, "Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. It specializes in novel therapeutics to treat chronic and retinal diseases. The company's product candidates consists of KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and Uveitis, KSI-201 for treatment resistant wet AMD and KSI-401 for dry AMD which are in clinical stage. Kodiak Sciences Inc. is based in CA, United States. " (2/20/2020)
  • 2. Chardan Capital analysts commented, "We thought it notable that CMO and CDO PhD spent 10 years at unrated Roche (Genentech), including as global head of late- stage ophthalmology, where his team was responsible for pivotal studies and he headed programs such as Lucentis Port Delivery. Kodiak platform address the limitations (e.g. treatment burden) of anti-VEGF therapies (>$10.5 bn in 2018 sales). With KSI-301, Kodiak hopes to address the leading global causes of blindness, namely aging and diabetes. Despite the size of the existing anti- VEGF market, an unmet medical need exists since, after 3 years or so of treatment, patients (under optimal care) typically have vision close to or worse than when the patients started anti-VEGF treatment." (6/13/2019)

Has Kodiak Sciences been receiving favorable news coverage?

News coverage about KOD stock has trended very positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kodiak Sciences earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutKodiak Sciences.

Who are some of Kodiak Sciences' key competitors?

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Amarin (AMRN), AT&T (T), Verizon Communications (VZ), Broadcom (AVGO), Cisco Systems (CSCO), AbbVie (ABBV), salesforce.com (CRM) and Honeywell International (HON).

Who are Kodiak Sciences' key executives?

Kodiak Sciences' management team includes the following people:
  • Dr. Victor Perlroth, Co-Founder, Chairman, CEO & Pres (Age 45)
  • Mr. John A. Borgeson MBA, CPA, Sr. VP & CFO (Age 57)
  • Dr. Hong Liang, Sr. VP of Discovery Medicine (Age 46)
  • Dr. Jason S. Ehrlich M.D., Ph.D., Chief Medical Officer & Chief Devel. Officer (Age 42)
  • Dr. Joel Naor M.D., MSc, MBA, VP of Clinical R&D Operations

When did Kodiak Sciences IPO?

(KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.

What is Kodiak Sciences' stock symbol?

Kodiak Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "KOD."

Who are Kodiak Sciences' major shareholders?

Kodiak Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.89%), Perceptive Advisors LLC (9.89%), ArrowMark Colorado Holdings LLC (4.05%), State Street Corp (1.80%), Geode Capital Management LLC (0.88%) and Renaissance Technologies LLC (0.81%). Company insiders that own Kodiak Sciences stock include Bros Advisors Lp Baker, Hong Liang, Jason Ehrlich, Richard S Levy and Robert Profusek. View institutional ownership trends for Kodiak Sciences.

Which institutional investors are selling Kodiak Sciences stock?

KOD stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., ArrowMark Colorado Holdings LLC, Schonfeld Strategic Advisors LLC, Nuveen Asset Management LLC, EAM Global Investors LLC, EAM Investors LLC, Russell Investments Group Ltd., and M&T Bank Corp. Company insiders that have sold Kodiak Sciences company stock in the last year include Hong Liang, and Jason Ehrlich. View insider buying and selling activity for Kodiak Sciences.

Which institutional investors are buying Kodiak Sciences stock?

KOD stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, State Street Corp, FMR LLC, Parkman Healthcare Partners LLC, Geode Capital Management LLC, TD Asset Management Inc., and Renaissance Technologies LLC. Company insiders that have bought Kodiak Sciences stock in the last two years include Bros Advisors Lp Baker, Richard S Levy, and Robert Profusek. View insider buying and selling activity for Kodiak Sciences.

How do I buy shares of Kodiak Sciences?

Shares of KOD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kodiak Sciences' stock price today?

One share of KOD stock can currently be purchased for approximately $47.84.

How big of a company is Kodiak Sciences?

Kodiak Sciences has a market capitalization of $2.13 billion.  View additional information about Kodiak Sciences.

What is Kodiak Sciences' official website?

The official website for Kodiak Sciences is http://www.kodiak.com/.

How can I contact Kodiak Sciences?

The company can be reached via phone at 650-281-0850.

MarketBeat Community Rating for Kodiak Sciences (NYSE KOD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  143
MarketBeat's community ratings are surveys of what our community members think about Kodiak Sciences and other stocks. Vote "Outperform" if you believe KOD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel